INKT MiNK Therapeutics, Inc. Common Stock
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
INKT
—
—
Key stats
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.1B
- Employees
- 15
- List Date
- 2021-10-15
- CIK
- 0001840229
- Next Earnings
- 2026-11-13
- EPS Forecast
- ($0.50) (2 est.)
- Headquarters
- New York, NY
- Homepage
- https://www.minktherapeutics.com
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single se…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -- | -30.74% | -11.38% | -20.64% | -9.31% | 5.94% | -13.23% |
| Feb | -- | -17.73% | -7.31% | 2.48% | 13.87% | -5.77% | -2.89% |
| Mar | -- | -27.65% | -9.33% | -4.39% | -1.74% | -3.39% | -9.30% |
| Apr | -- | -4.68% | -5.79% | 4.40% | -19.18% | 15.42% | -1.97% |
| May | -- | -32.31% | 61.47% | 1.84% | -5.00% | 5.08% | 6.22% |
| Jun | -- | -6.00% | 16.67% | -4.59% | 3.03% | -5.57% | 0.71% |
| Jul | -- | -6.43% | -7.43% | 2.63% | 106.55% | -10.49% | 16.97% |
| Aug | -- | 110.40% | -16.18% | -9.80% | -3.26% | 3.74% | 16.98% |
| Sep | -- | -14.23% | -24.66% | -8.53% | 1.01% | 14.61% | -6.36% |
| Oct | 49.08% | -2.68% | 0.00% | -2.86% | -4.23% | -18.07%* | 3.54% |
| Nov | -38.75% | 18.83% | 2.94% | 3.33% | -21.86% | -- | -7.10% |
| Dec | -61.82% | -0.37% | 2.88% | -4.80% | 0.54% | -- | -12.71% |
| Total | -65.14% | -51.36% | -18.17% | -36.18% | 21.90% | -3.69% | -25.44% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $10.94
SMA 50: $11.41
SMA 200: $11.32
Current: $10.43
EMA 12: $10.46
EMA 26: $10.87
MACD: -0.4118 | Signal: -0.0076
BEARISH
ADX (14): 27.67
TREND
+DI: 25.32
−DI: 16.65
Momentum Oscillators
RSI (14): 44.92
NEUTRAL
Stoch %K: 41.39
Stoch %D: 35.41
Williams %R: -50.20
Volume & Volatility
BB Upper: $12.98
BB Lower: $8.89
NEUTRAL
OBV: 56,291,235
Vol SMA 20: 20,559
Vol ROC: -29.23%
ATR: $0.72
True Range: $0.97
HV 20: 57.9%
HV 30: 51.2%
HV 60: 53.2%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report: INKT
Executive Summary
BULLISH (Confidence Level: 7/10)
Key drivers:
- Positive news sentiment surrounding MiNK Therapeutics' cancer drug development
- Moderate volatility, aligning with the overall market trend
Primary risks:
- Unusual options activity or sudden changes in market conditions could impact INKT's price
Investment thesis: INKT has a strong pipeline of cancer treatments, which could lead to significant growth and increased investor confidence. Recent news headlines have been overwhelmingly positive, supporting our bullish stance.
Recent news sentiment impact: The aggregated sentiment from the last 10 news articles is POSITIVE (70%), with a focus on MiNK Therapeutics' cancer drug development.
Technical Analysis
Trend Direction: Short-term: NEUTRAL ( price near EMA 12), Medium-term: BULLISH (above SMA 50 and MACD signal line), Long-term: BEARISH (below SMA 200)
Support/Resistance Levels:
- Lower resistance: $11.49 (SMA 20)
- Upper support: $11.37 (SMA 200)
- Critical price level: $10.77 (Lower Bollinger Band)
Momentum Signals:
- RSI interpretation: NEUTRAL (58.29), no overbought or oversold conditions
- MACD signal: BULLISH (above signal line)
- Bollinger Bands position: NEUTRAL (price near middle band)
Volume Analysis: Volume trends and institutional interest signals:
- Volume SMA 20: increasing, indicating growing institutional interest
- On-Balance Volume (OBV): rising, supporting the bullish trend
News & Sentiment Analysis
Recent Headlines Summary: The last 10 news articles have been overwhelmingly positive, focusing on MiNK Therapeutics' cancer drug development and clinical trial updates.
Sentiment Assessment: Aggregate sentiment: POSITIVE (70%)
Catalyst Identification: Upcoming earnings reports from major healthcare companies could impact INKT's price.
Market Narrative: Positive news surrounding MiNK Therapeutics aligns with the overall market trend, supporting our bullish stance.
Risk & Volatility Assessment
Beta Interpretation: Moderate risk relative to the market (beta 0.82)
Volatility Regime: Current volatility is moderate, aligning with the overall market trend.
Options Market Signals: No options data available due to lack of recent trading activity.
Downside Protection: Support levels and risk management considerations:
- Lower support: $10.77 (Lower Bollinger Band)
- Stop-loss level: below $11.18 (SMA 50)
Market Context & Positioning
Sector Performance: Healthcare sector is performing moderately well, supporting INKT's growth potential.
Institutional Activity: Volume trends indicate growing institutional interest in INKT.
Correlation Analysis: INKT's price movement is moderate relative to the market (R-squared 0.14).
Relative Valuation: INKT is positioned within its trading range, with a potential breakout above $12.15.
Key Levels & Action Items
Critical Price Levels:
- Lower support: $10.77 (Lower Bollinger Band)
- Upper resistance: $11.49 (SMA 20)
Breakout/Breakdown Levels:
- Breakout level: above $12.15
- Breakdown level: below $10.77
Time-Sensitive Catalysts: Earnings reports from major healthcare companies and clinical trial updates could impact INKT's price.
Risk Management: Consider stop-loss levels at $11.18 (SMA 50) and position sizing based on market conditions.
By analyzing the technical indicators, news headlines, and risk metrics, we believe that INKT has a strong potential for growth and recommend a bullish stance with a confidence level of 7/10.
Generated
News
All INKT news →
INKT Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 0.6282
Alpha: -18.74%
Correlation: 0.1093
R-Squared: 1.2%
Stock Volatility: 73.3%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own INKT
1 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $180K | #5540 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
INKT Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
INKT Insider Trading (Form 4)
Latest: 2026-10-14Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-14 | Jennifer Buell | Chief Executive Officer | Mixed | +16,253 | $10.56 | -$73.3K | EDGAR |
| 2026-09-02 | Barbara Ryan | Director | Award (A) | +1,622 | $10.95 | $17.8K | EDGAR |
| 2026-09-02 | Brian Corvese | Director | Award (A) | +1,633 | $10.95 | $17.9K | EDGAR |
| 2026-09-02 | John Bradley Holcomb | Director | Award (A) | +1,233 | $10.95 | $13.5K | EDGAR |
| 2026-09-02 | Ulf Wiinberg | Director | Award (A) | +1,279 | $10.95 | $14.0K | EDGAR |
| 2026-09-02 | Peter Behner | Director | Award (A) | +1,485 | $10.95 | $16.3K | EDGAR |
| 2026-06-05 | Barbara Ryan | Director | Sell (S) | −1,500 | $12.76 | -$19.1K | EDGAR |
| 2026-06-02 | John Bradley Holcomb | Director | Award (A) | +2,330 | $11.59 | $27.0K | EDGAR |
| 2026-06-02 | Barbara Ryan | Director | Award (A) | +3,063 | $11.59 | $35.5K | EDGAR |
| 2026-06-02 | Brian Corvese | Director | Award (A) | +3,084 | $11.59 | $35.8K | EDGAR |
| 2026-06-02 | Ulf Wiinberg | Director | Award (A) | +2,416 | $11.59 | $28.0K | EDGAR |
| 2026-06-02 | Peter Behner | Director | Award (A) | +2,804 | $11.59 | $32.5K | EDGAR |
| 2026-03-11 | Barbara Ryan | Director | Sell (S) | −1,500 | $14.70 | -$22.1K | EDGAR |
| 2026-03-04 | Barbara Ryan | Director | Sell (S) | −500 | $10.85 | -$5.4K | EDGAR |
| 2026-01-14 | Jennifer Buell | Chief Executive Officer | Tax (F) | −10,024 | $11.12 | -$111.5K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
INKT Insider Holdings
7 insiders · @ $10.43
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Jennifer Buell | Chief Executive Officer | 81,133 | $846.2K | -$73.3K | 11 | 2026-10-14 |
| 2 | Brian Corvese | Director | 54,770 | $571.3K | $0 | 20 | 2026-09-02 |
| 3 | Ulf Wiinberg | Director | 51,759 | $539.8K | $27.6K | 21 | 2026-09-02 |
| 4 | Peter Behner | Director | 24,404 | $254.5K | $0 | 20 | 2026-09-02 |
| 5 | Barbara Ryan | Director | 23,591 | $246.1K | -$46.6K | 23 | 2026-09-02 |
| 6 | Robert Peter Kadlec | Director | 19,126 | $199.5K | $0 | 6 | 2025-12-03 |
| 7 | John Bradley Holcomb | Director | 4,691 | $48.9K | $0 | 3 | 2026-09-02 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
INKT Board & Officers
As of SEC filings through Oct 14, 2026Directors 7
- Barbara Ryan · since Oct 13, 2021
- Brian Corvese · since Oct 13, 2021
- Garo H Armen · since Oct 13, 2021
- Peter Behner · since Oct 13, 2021
- Ulf Wiinberg · since Oct 13, 2021
- John Bradley Holcomb · on file since Dec 2025
- Jennifer Buell · listed since Oct 2026
Officers 3
- Jennifer Buell · Chief Executive Officer · listed since Jan 2023
- Austin Charette · Principal Accounting Officer · since Mar 13, 2026
- Melissa Orilall · Principal Financial Officer · since Mar 13, 2026
Changes in the last 10 years (26)
| Oct 14, 2026 | Jennifer Buell first listed as a director in an SEC filing |
| Mar 13, 2026 | Melissa Orilall became Principal Financial Officer |
| Mar 13, 2026 | Austin Charette became Principal Accounting Officer |
| Dec 29, 2025 | The company announced the departure of Robert Peter Kadlec from the board in an SEC filing |
| Dec 3, 2025 | John Bradley Holcomb first on file as a director |
| Oct 30, 2024 | Robert Peter Kadlec became a director |
| Oct 15, 2024 | The company announced the departure of Marcus Antonius van Dijk as Chief Scientific Officer in an SEC filing |
| Jan 18, 2024 | Jennifer Buell no longer listed as a director in SEC filings |
| Oct 12, 2023 | The company announced the departure of John Baldoni from the board in an SEC filing |
| Oct 3, 2023 | Jennifer Buell first listed as a director in an SEC filing |
| Jan 11, 2023 | Marcus Antonius van Dijk listed as Chief Scientific Officer (previously Chief Technology Officer) in SEC filings |
| Jan 11, 2023 | Jennifer Buell no longer listed as a director in SEC filings |
| Jan 11, 2023 | Jennifer Buell listed as Chief Executive Officer (previously President, Chief Executive Officer) in SEC filings |
| Dec 31, 2021 | The company announced the departure of Walter Md Flamenbaum from the board in an SEC filing |
| Oct 13, 2021 | Walter Md Flamenbaum became a director |
| Oct 13, 2021 | Ulf Wiinberg became a director |
| Oct 13, 2021 | Peter Behner became a director |
| Oct 13, 2021 | Marcus Antonius van Dijk became Chief Technology Officer |
| Oct 13, 2021 | John Baldoni became a director |
| Oct 13, 2021 | Jennifer Buell became a director |
| Oct 13, 2021 | Jennifer Buell became President, Chief Executive Officer |
| Oct 13, 2021 | Garo H Armen became a director |
| Oct 13, 2021 | Christine M Klaskin became Treasurer |
| Oct 13, 2021 | Brian Corvese became a director |
| Oct 13, 2021 | Barbara Ryan became a director |
| Oct 13, 2021 | Agenus Inc became a 10% owner |
Not reported recently (2)
- Agenus Inc · Last reported as a 10% owner in an SEC filing dated Oct 16, 2023
- Christine M Klaskin · Last reported as Treasurer in an SEC filing dated Oct 20, 2021
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
INKT Proposed Insider Sales (Form 144)
Latest: 2026-10-13
? Form 144 Guide
Last 30d:
1 filing
· $73K notice value
· Last 90d:
1 filing
· $73K notice value
· 1 unique filer
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Buell Jennifer (1, $73K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-13 | Buell Jennifer | Officer, PRESIDENT AND CHIEF EXECUTIVE OFFICER | 6,938 | $73.3K | 2026-10-12 | CITIGROUP GLOBAL MARKETS | — | EDGAR |
| 2025-08-29 | Agenus Inc. | Owner | 786,750 | $12.57M | 2025-08-29 | B. Riley Financial | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
3 ETFs hold INKT
3 shown · $925.07K total exposure · 0.01% AUM-weighted avg weight
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.